In:
Transfusion, Wiley, Vol. 53, No. 9 ( 2013-09), p. 2053-2060
Abstract:
Allergic transfusion reactions ( ATR s), particularly those caused by plasma‐rich platelet concentrates ( P ‐ PC s), are an important concern in transfusion medicine. Replacing P ‐ PCs with PCs containing M ‐sol ( M ‐sol‐ R ‐ PC s) is expected to prevent ATR s. However, this has not yet been verified by sufficient clinical evidence. Study Design and Methods A retrospective cohort study was performed between 2008 and 2011. Pediatric patients with hematologic disorders, solid tumors, primary immunodeficiency disorders, or inherited metabolic disorders were transfused with M ‐sol‐ R ‐ PCs between 2010 and 2011; the transfusions of P ‐ PC s administered between 2008 and 2011 were compared in terms of frequency and severity of ATR s, corrected count increment ( CCI ), and occurrence of bleeding. Data were collected for 6 consecutive months on a per‐patient basis. Results Data obtained during 2008 to 2011 showed that of the 78 patients receiving 515 P ‐ PC transfusions, 14 (17.9%) had 17 ATR s (3.3%); 14 and three ATR s were of Grades 1 and 2, respectively. In 2010 to 2011, 49 patients received 620 transfusions of M ‐sol‐R‐ PCs , and two patients (4.1%) had Grade 1 ATR s (0.3%). Thus, the frequency of ATR s per bag and per patient differed significantly between the two transfusions. No steroid agents were used for the prevention or treatment of ATR s in the M ‐sol‐ R ‐ PC group. The CCI (24 hr) for M ‐sol‐ R ‐ PCs did not differ from that for P ‐ PCs . Conclusion M ‐sol‐ R ‐ PCs were found to be effective in preventing ATR s without loss of transfusion efficiency in children; however, its efficacy should be further evaluated in prospective clinical trials.
Type of Medium:
Online Resource
ISSN:
0041-1132
,
1537-2995
DOI:
10.1111/trf.2013.53.issue-9
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2018415-3
Permalink